Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $125000.0.

  • Centessa Pharmaceuticals' Gains from Investment Securities fell 8711.34% to $125000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $125000.0, marking a year-over-year decrease of 9664.97%. This contributed to the annual value of $9.7 million for FY2023, which is 481407.77% up from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Gains from Investment Securities is $125000.0, which was down 8711.34% from -$3.7 million recorded in Q4 2024.
  • In the past 5 years, Centessa Pharmaceuticals' Gains from Investment Securities ranged from a high of $9.7 million in Q1 2023 and a low of -$3.7 million during Q4 2024
  • Its 4-year average for Gains from Investment Securities is $1.6 million, with a median of $547500.0 in 2024.
  • The largest annual percentage gain for Centessa Pharmaceuticals' Gains from Investment Securities in the last 5 years was 8711.34% (2025), contrasted with its biggest fall of 8711.34% (2025).
  • Over the past 4 years, Centessa Pharmaceuticals' Gains from Investment Securities (Quarter) stood at -$206000.0 in 2022, then surged by 4814.08% to $9.7 million in 2023, then tumbled by 138.42% to -$3.7 million in 2024, then surged by 103.35% to $125000.0 in 2025.
  • Its Gains from Investment Securities was $125000.0 in Q3 2025, compared to -$3.7 million in Q4 2024 and $970000.0 in Q3 2024.